- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
This strategic framework provides a road map to scale-up PPTCT services in the most efficient manner, where value for money is achieved with the promise that no infected mother will be missed and no child will be born with HIV, where every HIV exposed infant will receive the much needed HIV test at 6 weeks of age, and linked to treatment where required.
Preventing and managing the emergence of HIVDR is a key component of a comprehensive and effective HIV response, and should be integrated into broader efforts to ensure sustainability and greatest impact. It is essential that actions to monitor, prevent and respond to HIVDR are implemented at the clinical, programme and policy levels to address the many drivers of HIVDR.
The goal of this Global Action Plan is to articulate synergistic actions that will be required to prevent HIVDR from undermining efforts to achieve global targets on health and HIV, and to provide the most effective treatment to all people living with HIV including adults, key populations, pregnant and breastfeeding women, children and adolescents.
Find HIV data on PMTCT, ANC, pregnant women, ART in Nepal.
This report provides in-depth technical discussions in areas that have direct implications to the containment of AMR as a development agenda. The report is organized in five chapters which served as the technical background documents for the Biregional Technical Consultation on AMR in Asia, 14-15 April 2016. More information from the meeting is available in the WHO Meeting Report: Biregional Technical Consultation on Antimicrobial Resistance in Asia. The meeting was the first time senior officials from the Ministry of Health and Ministry of Agriculture across Asia came together to tackle AMR.
Keywords: drug resistance, microbial, infection control
The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments. To date, the selection of pathogens for R&D activities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, and availability of specific technologies. Previous PPLs, issued by the Centers for Disease Control and Prevention.
The present guidance was developed with the support of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) to assist countries and other stakeholders in the establishment and development of programmes of integrated surveillance of antimicrobial resistance in the foodborne bacteria (i.e., bacteria commonly transmitted by food) by taking a One Health approach. This guidance document replaces the previous version published in 2013.
Keywords: antimicrobial use, analysis, reporting, data
In this Region, most mothers and children receive health services during pregnancy, delivery and in the months after birth. However, when services for HIV, hepatitis B and syphilis are planned and delivered through separate, uncoordinated, vertical programmes in the health system.
This report is an account of the Region’s progress in developing and implementing NAPs. The report provides a platform to track what is going well, and to identify areas where extra efforts are needed. In the report, the regional roadmap for strengthening national AMR prevention and containment programmes is analysed with a specific methodology. The results gathered have been compiled to contribute to country profiles which make the report more useful.
Keywords: AMR, situation analysis, surveillance, prevention
Saving lives, preventing new HIV infections, preventing mother-to-child transmission of HIV, post-exposure prophylaxis for averting HIV infection, restoring respect and dignity to people living with HIV, pre-exposure prophylaxis for people at higher risk, preventing TB, TB-related deaths and TB transmission, restoring employment, reducing the number of children becoming orphans, and reducing maternal mortality.
This WHO Global hepatitis report describes, for the first time, the global and regional estimates on viral hepatitis in 2015, setting the baseline for tracking progress in implementing the new global strategy.
The report focuses on hepatitis B and C, which are responsible for 96% of all hepatitis mortality. It presents data along the five strategic directions (strategic information, interventions, equity, financing and innovation) – key pillars of the GHSS to facilitate monitoring of progress in countries, regions and globally, and to measure the impact of interventions on reducing new infections and saving lives between 2015 and 2030.
Download Executive Summary